Enliven Therapeutics (NASDAQ:ELVN) CFO Sells $316,787.52 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $53.95 on Friday. The stock has a market cap of $3.29 billion, a P/E ratio of -32.31 and a beta of 0.24. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $55.79. The firm’s fifty day moving average price is $46.48 and its 200-day moving average price is $38.37.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. JonesTrading raised their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Guggenheim started coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in ELVN. Commodore Capital LP increased its position in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Vestal Point Capital LP lifted its position in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares during the last quarter. Vanguard Group Inc. boosted its stake in Enliven Therapeutics by 5.9% in the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares in the last quarter. Finally, State Street Corp boosted its stake in Enliven Therapeutics by 9.1% in the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after buying an additional 87,725 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.